Plain-English translation of NCT06052176 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing intravenous albumin—a protein naturally found in blood—to see if it can help improve memory and thinking problems in people with advanced liver disease (cirrhosis) who have experienced hepatic encephalopathy, a condition where the liver cannot filter toxins properly and this affects the brain. A previous study showed promising results: people who received albumin had better thinking and memory skills, and these improvements lasted even after treatment stopped. This new study will carefully measure how long the benefits last and how the medication works in the body.
Even when patients take medicines to control their brain fog, some still struggle with thinking and memory problems. Doctors need to understand whether this medication could offer a longer-lasting solution and exactly how it helps the brain recover.
You likely qualify if…
You likely don't qualify if…
Over 8 weeks, you will visit the clinic several times to receive intravenous infusions—sometimes of albumin and sometimes of saline (salt water), though neither you nor the researchers will know which you're getting at each visit. Before, during, and after the infusions, you'll complete simple thinking and memory tests, answer questions about how you're feeling, and have blood samples taken to measure how the treatment affects your body. You'll be your own comparison, so the researchers can track how each treatment affects you personally.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States